An FDA committee has unanimously recommended Schering-Plough's sugammadex for approval. The drug, which is being developed to reverse the effects of anesthesia used during surgery, allows doctors to reverse the depth of a patient's muscle relaxation within minutes. The FDA usually follows the committee's recommendation. The drug gained priority review in January.
Schering gained sugammadex in its massive $14.4 billion buyout of Organon one year ago. Sugammadex will be sold under the name Bridion if approved.